These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 21930612

  • 1. Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy.
    Beigi R, Noguchi L, Parsons T, Macio I, Kunjara Na Ayudhya RP, Chen J, Hendrix CW, Mâsse B, Valentine M, Piper J, Watts DH.
    J Infect Dis; 2011 Nov 15; 204(10):1527-31. PubMed ID: 21930612
    [Abstract] [Full Text] [Related]

  • 2. A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.
    Yang KH, Hendrix C, Bumpus N, Elliott J, Tanner K, Mauck C, Cranston R, McGowan I, Richardson-Harman N, Anton PA, Kashuba AD.
    PLoS One; 2014 Nov 15; 9(10):e106196. PubMed ID: 25350119
    [Abstract] [Full Text] [Related]

  • 3. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
    Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, Salata R, Soto-Torres L, Patterson K, Minnis AM, Gandham S, Gomez K, Richardson BA, Bumpus NN.
    PLoS One; 2013 Nov 15; 8(1):e55013. PubMed ID: 23383037
    [Abstract] [Full Text] [Related]

  • 4. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.
    Dobard C, Sharma S, Martin A, Pau CP, Holder A, Kuklenyik Z, Lipscomb J, Hanson DL, Smith J, Novembre FJ, García-Lerma JG, Heneine W.
    J Virol; 2012 Jan 15; 86(2):718-25. PubMed ID: 22072766
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.
    Johnson TJ, Clark MR, Albright TH, Nebeker JS, Tuitupou AL, Clark JT, Fabian J, McCabe RT, Chandra N, Doncel GF, Friend DR, Kiser PF.
    Antimicrob Agents Chemother; 2012 Dec 15; 56(12):6272-83. PubMed ID: 23006751
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel.
    Schwartz JL, Rountree W, Kashuba AD, Brache V, Creinin MD, Poindexter A, Kearney BP.
    PLoS One; 2011 Dec 15; 6(10):e25974. PubMed ID: 22039430
    [Abstract] [Full Text] [Related]

  • 12. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue.
    Louissaint NA, Cao YJ, Skipper PL, Liberman RG, Tannenbaum SR, Nimmagadda S, Anderson JR, Everts S, Bakshi R, Fuchs EJ, Hendrix CW.
    AIDS Res Hum Retroviruses; 2013 Nov 15; 29(11):1443-50. PubMed ID: 23600365
    [Abstract] [Full Text] [Related]

  • 13. Differences in Local and Systemic TFV PK Among Premenopausal Versus Postmenopausal Women Exposed to TFV 1% Vaginal Gel.
    Thurman AR, Chandra N, Yousefieh N, Kimble T, Anderson SM, Cottrell M, Sykes C, Kashuba A, Schwartz JL, Doncel GF.
    J Acquir Immune Defic Syndr; 2018 May 01; 78(1):82-92. PubMed ID: 29424790
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques.
    Pereira LE, Clark MR, Friend DR, Garber DA, McNicholl JM, Hendry RM, Doncel GF, Smith JM.
    Antimicrob Agents Chemother; 2014 May 01; 58(5):2665-74. PubMed ID: 24566178
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study.
    Chen J, Flexner C, Liberman RG, Skipper PL, Louissaint NA, Tannenbaum SR, Hendrix CW, Fuchs EJ.
    J Acquir Immune Defic Syndr; 2012 Dec 15; 61(5):593-9. PubMed ID: 23187888
    [Abstract] [Full Text] [Related]

  • 17. Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.
    Jackson A, Moyle G, Watson V, Tjia J, Ammara A, Back D, Mohabeer M, Gazzard B, Boffito M.
    J Acquir Immune Defic Syndr; 2013 Mar 01; 62(3):275-81. PubMed ID: 23274933
    [Abstract] [Full Text] [Related]

  • 18. Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel.
    Gao Y, Katz DF.
    PLoS One; 2013 Mar 01; 8(9):e74404. PubMed ID: 24040241
    [Abstract] [Full Text] [Related]

  • 19. Vaginal deployment and tenofovir delivery by microbicide gels.
    Gao Y, Yuan A, Chuchuen O, Ham A, Yang KH, Katz DF.
    Drug Deliv Transl Res; 2015 Jun 01; 5(3):279-94. PubMed ID: 25874971
    [Abstract] [Full Text] [Related]

  • 20. FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir.
    Bunge KE, Dezzutti CS, Hendrix CW, Marzinke MA, Spiegel HML, Moncla BJ, Schwartz JL, Meyn LA, Richardson-Harman N, Rohan LC, Hillier SL.
    J Int AIDS Soc; 2018 Aug 01; 21(8):e25156. PubMed ID: 30101439
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.